Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Authors: Fortin Jessica S, Benskey Matthew J, Lookingland Keith J, Patterson Jon S, Howey Erin B, Goudreau John L, Schott Harold C
Journal: BMC veterinary research
Summary
# Editorial Summary: Pergolide Restores Dopaminergic Function in Equine PPID Pituitary pars intermedia dysfunction develops as horses age through progressive loss of hypothalamic dopaminergic innervation, triggering pathological expansion of melanotrope cells; pergolide, a dopamine receptor agonist used clinically to manage PPID, has demonstrated clinical efficacy but its effects on underlying neurochemical pathology remain poorly characterised. Researchers measured dopamine concentrations and tyrosine hydroxylase (TH) expression in pituitary tissue harvested from 18 horses across four groups—untreated PPID cases, pergolide-treated PPID cases (6 months at 2 µg/kg daily), aged controls, and young controls—using high-performance liquid chromatography and Western blot analysis. Pergolide-treated horses showed substantially restored dopamine levels and TH expression in the pars intermedia compared to untreated PPID-affected horses, approaching concentrations seen in age-matched controls without PPID. These findings suggest pergolide's therapeutic benefit extends beyond symptomatic management to partially reverse the neurochemical deficits underlying PPID pathogenesis, providing mechanistic support for dopamine agonist therapy and informing evidence-based treatment protocols for this common geriatric condition. For practitioners, this work reinforces pergolide's role in managing PPID whilst highlighting that biochemical restoration may require sustained treatment and potentially explains variable clinical responses at different dosing regimens.
Read the full abstract on PubMed
Practical Takeaways
- •Pergolide treatment effectively restores the underlying biochemical defect in PPID by replenishing dopamine and reactivating dopamine-producing enzymes, supporting its use as a disease-modifying therapy rather than just symptom management
- •The biochemical restoration occurs within 6 months of treatment, which aligns with observed clinical improvement timelines in PPID-affected horses
- •This evidence supports continued pergolide therapy as the standard pharmacological approach for managing PPID in aged horses
Key Findings
- •Pergolide treatment restored dopamine concentrations in pars intermedia tissue of PPID-affected horses to levels comparable with untreated aged and young control horses
- •Pergolide treatment restored tyrosine hydroxylase immunoreactivity in pars intermedia tissue of PPID-affected horses
- •Untreated PPID-affected horses showed markedly reduced dopamine concentrations and tyrosine hydroxylase expression compared to control horses
- •Six months of pergolide at 2 µg/kg once daily orally produced biochemical restoration of dopaminergic function in pituitary pars intermedia